Sonrotoclax plus zanubrutinib yielded deep, durable responses at the recommended phase 2 dose in relapsed/refractory MCL.
Assessing a Novel BCL-2 Inhibitor–Based Combination in R/R Mantle Cell Lymphoma
Advertisement
Advertisement
Trending on OncLive
1
Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC
2
Oral Administration Afforded by CDK2 Inhibitors May Ease the Price of Admission in Platinum-Resistant Ovarian Cancer
3
MAIC Shows Improved PFS With Zanubrutinib Over Ibrutinib in Treatment-Naive CLL
4
Iza-Bren Improves Survival in Unresectable, Locally Advanced or Metastatic TNBC
5